BOSTON (TheStreet) -- Happy Thanksgiving! An early Biotech Stock Mailbag:
Nico asks, "Aveo Pharmaceuticals (AVEO) has to be oversold at this point, right? Is FDA likely to make a big stink about a small unfavorable trend in 1-year overall survival data even though (a) median OS has not yet been reached; (b) all kidney cancer drug approvals have been based on progression-free survival (PFS) and tivozanib showed the single-highest PFS ever shown in a phase III clinical trial; and (c) the overall survival trend is easily explained by the crossover trial design."
Aveo is a cautionary tale in oncology drug development. The company deserves huzzahs for running a pivotal study in kidney cancer comparing tivozanib against an active comparator -- Onyx Pharmaceuticals' (ONXX) Nexavar. We see far too few clinical trials that compare one active drug against another.
Unfortunately, the mixed data that emerged from Aveo's tivozanib study have raised a lot of uncomfortable questions and caused the company a ton of trouble, which may explain why head-to-head drug studies are so rare.Tivozanib delayed the time before patients' kidney cancer started to grow (progression-free survival) by a median 11.9 months compared to 9.1 months for Nexavar -- a difference that was statistically significant and which achieved the study's primary endpoint. Tivozanib was also better tolerated than Nexavar, with fewer dose reductions and treatment discontinuations due to adverse events. But (and you knew this was coming), the analysis of overall survival -- a key secondary endpoint in the study -- was problematic. At one year, 81% of Nexavar patients were still alive compared to 77% of tivozanib patients. A second look at overall survival conducted a two years yielded a similar result. Oops. Aveo believes survival trended against tivozanib because more than 60% of the patients randomized to the Nexavar arm "crossed over" to receive tivozanib or some other therapy upon tumor progression. These Nexavar crossover patients are living longer because they benefited from treatment with two active kidney cancer drugs, Aveo argues. Meantime, only 24% of patients chosen to begin the trial in the tivozanib arm went on to a subsequent therapy.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV